Renaissance Group’s Anika Therapeutics ANIK Stock Holding History

Renaissance Group’s Portfolio ANIK Stock Details ANIK Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2016 Q4	–	Sell	-6,397	Closed	-$306K	–	282
2016 Q3	$306K	Sell	6,397 -137	-2%	-$6.77K	0.01%	217
2016 Q2	$351K	Sell	6,534 -36	-0.5%	-$1.7K	0.01%	169
2016 Q1	$294K	Sell	6,570 -3,121	-32%	-$127K	0.01%	208
2015 Q4	$370K	Sell	9,691 -161	-2%	-$6.16K	0.01%	158
2015 Q3	$314K	Buy	+9,852	New	+$344K	0.01%	187
2014 Q2	–	Sell	-8,504	Closed	-$350K	–	269
2014 Q1	$350K	Sell	8,504 -292	-3%	-$10.9K	0.01%	146
2013 Q4	$336K	Sell	8,796 -3,644	-29%	-$112K	0.01%	148
2013 Q3	$297K	Sell	12,440 -1,711	-12%	-$38.4K	0.01%	146
2013 Q2	$241K	Buy	+14,151	New	+$204K	0.01%	155

Other funds holding ANIK

BFA

BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return

Kayne Anderson Rudnick Investment Management Los Angeles, California $32.2B AUM 10.98% 1-Year Est. Return

TSW

Thompson Siegel & Walmsley Richmond, Virginia $5.57B AUM 9.46% 1-Year Est. Return

BTW

Boston Trust Walden Boston, Massachusetts $13.1B AUM 24.63% 1-Year Est. Return

BIT

BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return

AAM

AMI Asset Management Los Angeles, California $1.74B AUM 26.89% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Renaissance Group's ANIK Position: Q4 2016 in Review

Renaissance Group sold out of Anika Therapeutics (ANIK) in Q4 2016, closing a stake of 6,397 shares — an estimated $306K sold.

Renaissance Group first reported a position in ANIK in Q2 2013 and held it in 9 quarters. The position peaked at $370K in Q4 2015. 158 funds tracked by Wall St. Rank hold ANIK as of Q4 2016.

Renaissance Group reported no remaining Anika Therapeutics position as of Q4 2016 after selling out during the quarter.
Renaissance Group sold 6,397 Anika Therapeutics shares in Q4 2016, an estimated $306K.
Renaissance Group first reported a position in Anika Therapeutics in Q2 2013 and held it in 9 quarters.
Renaissance Group's Anika Therapeutics position peaked at $370K in Q4 2015.
158 funds tracked by Wall St. Rank held Anika Therapeutics as of Q4 2016.

Based on Renaissance Group's 13F filing for Q4 2016, filed 10 Feb 2017.